Europe's drug regulator starts safety review of anemia drugs

04/28/2007 | MarketWatch

The European Medicines Agency says it is reviewing anemia drugs from Amgen, Roche Holding and Shire PLC to see if they increase the risk of heart and cancer problems. In the meantime, the agency recommended confining the drugs to their indicated use, for treating anemia. The agency says it also is cooperating on a review of Johnson & Johnson's Eprex, sold as Procrit in the U.S.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Actuary
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL